HRTX

Sustol

Nausea Associated With Chemo

Stage (next event)

Expected Date

Quarterly Sales (Approved)

March 05, 2021 (Est)

Catalyst Info & Data Links

TITLE: Quarterly sales for Sustol for nausea associated (FDA-approved drug)


WHAT IS THE CATALYST EVENT?

  • Approved quarterly sales


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • March 05, 2021 (Est)


PRIOR DATA


PRESS RELEASES

Mechanism of Action

MECHANSIM OF ACTION/ RATIONALE

  • Granisetron is a selective 5-hydroxytryptamine3 (5-HT3) receptor antagonist with little or no affinity for other serotonin receptors, including 5-HT1, 5-HT1A, 5-HT1B/C, 5-HT2; for alpha1-, alpha2-, or beta-adrenoreceptors; for dopamine-D2; or for histamine-H1; benzodiazepine; picrotoxin or opioid receptors.


  • Serotonin receptors of the 5-HT3 type are located peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema. During chemotherapy that induces vomiting, mucosal enterochromaffin cells release serotonin, which stimulates 5-HT3 receptors. This evokes vagal afferent discharge, inducing vomiting. Animal studies demonstrate that, in binding to 5-HT3 receptors, granisetron blocks serotonin stimulation and subsequent vomiting after emetogenic stimuli such as cisplatin. In the ferret animal model, a single granisetron injection prevented vomiting due to high-dose cisplatin or arrested vomiting within 5 to 30 seconds.


COMPETITORS


5-hydroxytryptamine3 (5-HT3) receptor antagonist:

  • Aloxi ® (Palonosetron HCl) - Eisai

  • Zofran (ondansetron) - GSK

  • Kytril (granisetron) - Roche

  • Zuplenz (ondansetron) - Midatech Pharma


MARKET

  • ~4 million people per year receiving chemotherapy

  • ~CINV affects 70-80% of patients undergoing chemotherapy

  • See details

Updated by HC

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

FDA Decision on Heron's Non-Opioid Pain Med Imminent

Amp Core Q2 '19 Report

HRTX Opioid-Free Pain Med Candidate Continues to Impress

Amp Mid-Q1 '19 Update

HRTX Mid-Q1 '19 Update

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon